BrightSpring Health Services, Inc. Common Stock
BTSG
$59.13
-2.91%
BrightSpring Health Services, Inc. is a home and community-based healthcare services platform that delivers complementary pharmacy and provider services to complex patients across Medicare, Medicaid, and commercially insured populations. The company operates through two primary segments: Pharmacy Solutions and Provider Services, with Pharmacy Solutions generating the majority of revenue. As a relatively new public entity (listed in January 2024), BrightSpring has carved out a niche in managing high-acuity, chronic care populations through an integrated model. The current investor narrative centers on the company's robust revenue growth, strategic divestitures to streamline operations (such as the sale of ResCare Community Living), and its ability to expand margins while navigating a leveraged balance sheet. The stock has been a standout performer, up over 145% in the past year, drawing attention from both growth and value investors as it scales its platform.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$59.13
Related headlines
BTSG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $78.94 and implied upside of +33.5% versus the current price.
Average Target
$78.94
0 analysts
Implied Upside
+33.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $90
Analyst target range
The target price range spans from a low of $70.00 to a high of $90.00, representing a spread of $20.00, which indicates moderate uncertainty about the stock's fair value. The low target of $70 still implies a +19% upside, suggesting that even the most conservative analysts see value. The high target of $90 assumes continued strong growth and potential multiple expansion, likely driven by margin improvements and successful integration of acquisitions. The wide range reflects the variability in estimates for the company's future earnings power, but the overall bullish stance and recent upgrades (e.g., UBS and B of A Securities reiterating Buy) signal that analysts expect the positive momentum to persist. This strong consensus, combined with the stock's recent pullback, may present an attractive entry point for investors.
Bulls vs Bears: BTSG Investment Factors
BrightSpring presents a compelling growth story with accelerating revenue (25.6% YoY) and improving margins, but it carries significant leverage and a premium valuation. The bull case is supported by strong analyst targets (34% upside) and strategic divestitures, while the bear case highlights high debt, thin margins, and high volatility. Currently, the bull case has stronger evidence given the robust growth and margin expansion, but the key tension is whether the company can sustain its growth and margin improvements to justify the forward PE of 25.8x. If growth decelerates or margins stall, the stock could face multiple compression, making the valuation the central debate.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue surged 25.6% YoY to $3.61B, with sequential acceleration from $2.88B in Q1 2025 to $3.55B in Q4 2025. This momentum is driven by strong demand in Pharmacy Solutions and Provider Services, indicating robust execution.
- Improving Profitability Trajectory: Net margin expanded from 2.2% in Q4 2025 to 4.1% in Q1 2026, while EPS jumped from $0.38 to $0.73 sequentially. This margin expansion is a key driver of the forward PE compression from 39.8x trailing to 25.8x forward.
- Strong Analyst Consensus: With 17 analysts, the consensus is Strong Buy (mean 1.17) and the average target price of $78.94 implies 34% upside from the current $58.87. Even the low target of $70 suggests 19% upside, reflecting broad confidence.
- Strategic Divestiture Focus: The sale of ResCare Community Living to Sevita in March 2026 streamlines operations, allowing management to focus on higher-margin core segments. This strategic pivot is expected to enhance operational efficiency and margin expansion.
Bearish
- High Leverage and Interest Burden: Debt-to-equity ratio is 1.44, and Q1 2026 interest expense was $38.6M, which consumed 32% of operating income. This leverage amplifies financial risk, especially if interest rates remain elevated or cash flows weaken.
- Thin Gross Margins: Gross margin is only 11.8% (Q1 2026), reflecting a low-margin pharmacy business model. This leaves little room for error and makes the company sensitive to reimbursement rate changes or cost inflation.
- Elevated Valuation vs. Peers: Trailing PE of 39.8x is high for a healthcare services company with 11.8% gross margins. The forward PE of 25.8x still implies a premium, requiring flawless execution to justify the multiple.
- High Beta and Volatility: Beta of 1.88 indicates the stock is nearly twice as volatile as the market. Recent 1-month decline of -15.6% (vs. S&P +2.45%) shows significant downside risk during market corrections.
BTSG Technical Analysis
BrightSpring's stock has exhibited a powerful long-term uptrend, with a 1-year price change of +145.7%, significantly outperforming the S&P 500's +20.5% over the same period. The current price of $58.87 sits at approximately 80% of its 52-week range (low of $22.86, high of $73.75), indicating that while the stock has pulled back from its peak, it remains in the upper portion of its historical range. This positioning suggests the market still holds a positive long-term outlook, though the recent decline from the highs warrants attention for potential overextension or profit-taking.
Beta
1.88
1.88x market volatility
Max Drawdown
-21.5%
Largest decline past year
52-Week Range
$23-$74
Price range past year
Annual Return
+149.2%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | -14.8% | +5.5% |
| 3m | -4.1% | +1.7% |
| 6m | +42.7% | +12.2% |
| 1y | +149.2% | +18.6% |
| ytd | +54.0% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
BrightSpring has demonstrated robust revenue growth, with the most recent quarter (Q1 2026) reporting revenue of $3.61 billion, a 25.6% year-over-year increase. This growth is accelerating, as prior quarters showed sequential increases from $2.88 billion in Q1 2025 to $3.33 billion in Q3 2025 and $3.55 billion in Q4 2025. The company's revenue diversification is evident from segment data, with Commercial Insurance contributing $1.01 billion and Medicaid $405.7 million, though the majority comes from other sources. This strong top-line momentum is a key driver of the investment case, reflecting successful execution in its pharmacy and provider services.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+25.6%
YoY Comparison
Gross Margin
13.3%
Latest Quarter
Free Cash Flow
$412118000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Given that BrightSpring is profitable (net income of $148.8 million in Q1 2026), the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE stands at 39.8x, while the forward PE is 25.8x, indicating that the market expects significant earnings growth ahead. The gap between trailing and forward PE suggests an anticipated acceleration in profitability, which is supported by the company's improving net margin (4.1% in Q1 2026 vs. 2.2% in Q4 2025). This forward multiple is more reasonable for a company with 25% revenue growth, but it still implies a premium valuation that requires continued execution.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, BrightSpring carries a debt-to-equity ratio of 1.44, with interest expense of $38.6M in Q1 2026, representing 32% of operating income. This leverage increases vulnerability to rising interest rates or cash flow disruptions. The company's gross margin is thin at 11.8%, leaving limited buffer against cost inflation or reimbursement cuts. Additionally, net income is volatile, swinging from a loss in Q3 2024 to $148.8M in Q1 2026, indicating earnings instability that could surprise investors.